Zomedica Pharmaceuticals Corp Total Assets
Zomedica Pharmaceuticals Corp total assets. Based on the latest financial reports, Zomedica Pharmaceuticals Corp (ZOM) holds total assets worth $142.99 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Zomedica Pharmaceuticals Corp market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Zomedica Pharmaceuticals Corp (2012–2024)
Total assets of Zomedica Pharmaceuticals Corp from 2012 to 2024. This chart illustrates how Zomedica Pharmaceuticals Corp's total assets have evolved over time, based on quarterly financial data. See ZOM stock price and chart for real-time trading data and today's change.
Zomedica Pharmaceuticals Corp - Asset Composition Analysis
Zomedica Pharmaceuticals Corp Total Assets Breakdown (December 2024)
Zomedica Pharmaceuticals Corp total assets breakdown as of December 2024. Zomedica Pharmaceuticals Corp's total assets of $142.99 Million consist of 39.4% current assets and 60.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.4% |
| Accounts Receivable | $3.07 Million | 1.5% |
| Inventory | $5.06 Million | 2.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $52.54 Million | 25.3% |
| Goodwill | $45.56 Million | 22.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Zomedica Pharmaceuticals Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ZOM net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zomedica Pharmaceuticals Corp's current assets represent 39.4% of total assets in 2024, a decrease from 81.9% in 2012.
- Cash Position: Cash and equivalents constituted 3.4% of total assets in 2024, down from 81.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 25.3% of total assets.
Zomedica Pharmaceuticals Corp Competitors by Total Assets
Key competitors of Zomedica Pharmaceuticals Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Zomedica Pharmaceuticals Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.89 | 11.50 | 15.31 |
| Quick Ratio | 9.16 | 10.87 | 15.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $65.82 Million | $84.06 Million | $28.10 Million |
Zomedica Pharmaceuticals Corp - Advanced Valuation Insights
This section examines the relationship between Zomedica Pharmaceuticals Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -18.1% |
| Total Assets | $207.36 Million |
| Market Capitalization | $53.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zomedica Pharmaceuticals Corp's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Zomedica Pharmaceuticals Corp's assets decreased by 18.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zomedica Pharmaceuticals Corp (2012–2024)
The table below shows the annual total assets of Zomedica Pharmaceuticals Corp from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $207.36 Million | -18.10% |
| 2023-12-31 | $253.20 Million | -9.45% |
| 2022-12-31 | $279.61 Million | -0.28% |
| 2021-12-31 | $280.40 Million | +323.92% |
| 2020-12-31 | $66.14 Million | +1481.26% |
| 2019-12-31 | $4.18 Million | -30.67% |
| 2018-12-31 | $6.03 Million | +15.68% |
| 2017-12-31 | $5.22 Million | +6.98% |
| 2016-12-31 | $4.88 Million | +26.30% |
| 2015-12-31 | $3.86 Million | +2556.05% |
| 2014-12-31 | $145.34K | -31.29% |
| 2013-12-31 | $211.54K | +117.38% |
| 2012-12-31 | $97.31K | -- |
About Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more